Gts Securities LLC Neurocrine Biosciences Inc Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $3.35 Million - $4.47 Million	29,200 Added 595.92%	34,100 $3.93 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $379,494 - $415,251	-2,900 Reduced 37.18%	4,900 $674,000
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $469,440 - $517,464	3,600 Added 85.71%	7,800 $1.08 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $1.13 Million - $1.42 Million	-10,700 Reduced 71.81%	4,200 $553,000
Q3 2023 Nov 15, 2023	BUY	$94.02 - $117.1 $1.4 Million - $1.74 Million	14,900 New	14,900 $1.68 Million

623

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.